Nitto Denko Corporation has sold Aveva Drug Delivery Systems to Apotex
Lincoln International, a leading global middle market investment bank, has announced that Nitto Denko Corporation (“Nitto Denko”) has sold Aveva Drug Delivery Systems Inc. (“Aveva”) to Apotex Inc. (“Apotex”).
Aveva is a fully integrated, global developer and manufacturer of transdermal patches for branded and generic pharmaceuticals. Aveva’s manufacturing capabilities allow it to provide a complete transdermal solution from product feasibility to global commercialization for leading global pharmaceutical companies. Aveva is based in Miramar, Florida.
Apotex, the largest Canadian owned pharmaceutical company, has approximately 6,000 employees in 21 facilities producing 300 pharmaceuticals that are exported to 115 countries around the world. Apotex researches, develops, manufactures and distributes fine chemicals, non-prescription and private label medicines as well as disposable plastics for medical use. Apotex is privately owned and headquartered in Toronto, Canada.
Nitto Denko is Japan’s leading manufacturer of diversified materials and sells its products worldwide. Nitto Denko has the ability to add diverse functionality to sheets, films and other materials, utilizing several technologies such as polymer synthesis, adhesion and coating technologies. Nitto Denko was founded in 1918 and has over 33,000 employees around the world. Nitto Denko is publicly traded on the Tokyo Stock Exchange (TSE:6988) and headquartered in Osaka, Japan.
Lincoln International acted as the exclusive financial advisor to Nitto Denko and Aveva.
Meet our Senior Team
View More Transactions
Any information or testimonials contained in this post may not be representative of the experience of other clients and is no guarantee of future performance or success.